The epidemiology of multiple sclerosis (MS) is well studied owing to its prevalence and position as the main cause of non-traumatic disability among young adults. The usual age of onset for ...

[T]he epidemiology of multiple sclerosis is quite unique because there is a very striking geographical distribution. Professor Alberto Ascherio Researchers had known that there was something odd ...

Multiple sclerosis (MS) is one of the most widespread ... cases may fit into a designation of “benign MS.” However, the prevalence and criteria for benign MS are considered controversial.

SUFFICIENT information exists concerning the prevalence and the incidence patterns of multiple sclerosis in North America 1,2 so that communities can now be recognized and statistical ...

Multiple sclerosis (MS) is a complex and serious autoimmune disease for which there is no cure, and its prevalence is rising globally – especially in countries with advanced economies. Scientists need ...

As per DelveInsight, the Multiple Sclerosis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of ...

"We found a much higher prevalence of multiple sclerosis in Black Americans than previously thought," the investigators said. Other recent research has also focused on better understanding MS in ...

Dr Natalia Boven / Supplied The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study.

However, finding the connection was not easy. “It started with the observation that the epidemiology of multiple sclerosis is quite unique because there is a very striking geographical ...

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Bristol-Myers Squibb, TG Therapeutics, Hoffmann-La Roche, Atara Biotherapeutics ...